Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): Asia-Pacific (AP) trial subgroup analyses by baseline transaminase (ALT/AST)/α-fetoprotein (AFP) levelsShenghui Qin, Ann‐Lii Cheng, Tsai‐Hsiu Yang et al.|Journal of Clinical Oncology|2009Cited by 1
Impact of prior surgical resection with curative intent on the efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): Subset analysis of the Asia-Pacific (AP) studyT.-S. Yang, Ann‐Lii Cheng, C. Ts'ao et al.|Journal of Clinical Oncology|2009Cited by 1